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Background.Alpha-1antitrypsin deﬁciency (AAT)is an inherited condition that predisposesto lung and/orliver disease. Objective.
The current study examined the clinical features of the PiSS genotype. Methods. Nineteen study participants (PiSS) and 29
matched control participants (PiMM) were telephone interviewed using a standardized questionnaire. Demographic features,
cigarette smoking, vocation, medication history, and clinical diagnoses were compared. Statistical analysis was performed. Finally,
a comprehensive literature review was performed by two investigators. Results. 12/19 (63.2%) study participants reported the
presence of lung and/or liver disease compared to 12/29 (41.4%) control participants. There trended toward having a higher
frequency of medication allergies in the study population (42.11% versus 20.69%). Conclusions. The PiSS genotype was associated
with a similar incidence of obstructive lung disease to controls. Selective bias intrinsic in testing for AAT deﬁciency and the rarity
of the PiSS genotype will make future study of this association dependent on population-based tests.
1.Introduction
Alpha-1 antitrypsin (AAT) deﬁciency is an inherited condi-
tion that predisposes to lung and/or liver disease. The risk
for lung disease is increased by environmental exposures,
particularly cigarette smoking. SERPINA1, the gene that
codes for AAT, is located at 14q32.1 [1]. Currently, there
are approximately 100 allelic variants identiﬁed. The most
common allele is the M allele which codes for protease
inhibitor (Pi) M protein. As an autosomal codominant
genetic condition, most individuals are PiMM. The most
common severe deﬁciency allele is the Z allele which, in the
homozygous state (PiZZ), is associated with AAT plasma
levels that are 15% of normal. The S allele is associated
with AAT plasma levels approximately 60% of normal in the
homozygous state [2]. In the United States, the estimated
p h e n o t y p i cp r e v a l e n c e sa r e1i n1 7P i M S ,1i n3 6P i M Z ,
1 in 1058 PiSS, 1 in 1124 Pi SZ, and 1 in 4775 PiZZ.
The estimated US prevalence of the PiSS genotype from
population studies [3] would generate a PiS allele frequency
in the US population of approximately 3.1%.
While there exists a signiﬁcant amount of data regard-
ing the risks for symptoms associated with certain AAT
genotypes (PiMS, PiMZ, PiSZ, PiZZ), there is very little
information published regarding PiSS risks. Therefore, the
objective of the current study was to examine the clinical
features of individuals that have a PiSS genotype.
Essentialtoanaccurateclinicaldescriptionofindividuals
with any AAT polymorphism is a random selection of the
population to be studied. This feature is diﬃcult to achieve
for rare genetic variants. This report will characterize the
personal and family histories of individuals that are PiSS
who have participated in a large family testing program
usingﬁngerstickpolymerasechainreaction(PCR)genotypes
for AAT characterization, the Alpha-1 Coded Testing (ACT)
Study. In addition, a separate population who has enrolled in
the Alpha-1 Foundation Research Registry will be reported.
Finally, a review of populations of individuals that are PiSS
f r o mo t h e rs t u d i e si sp e r f o r m e d .
2.MaterialsandMethods
Participants were recruited through the ACT study and the
Alpha-1 Foundation Research Registry. The IRB approved
written informed consent for these studies allowed for2 Pulmonary Medicine
contact regarding future questionnaires and research. ACT
participants were drawn from a cohort of individuals usually
tested because of a family member with AAT deﬁciency.
Individuals identiﬁed through the Alpha-1 Foundation Reg-
istry were drawn from a group of 3090 registry participants
with severe AAT deﬁciency or the carrier state. Since
individuals with symptoms are more likely to be tested
for AAT deﬁciency, the participants of the ACT Study and
the Research Registry do not represent population-based
cohorts. Therefore, to approximate the same biases in a
control population, each individual with the PiSS genotype
wasrandomlyage,sex,race,andUSstatematchedtoanACT
participant with the PiMM genotype as a control.
Study participants were telephone interviewed by a
certiﬁed genetic counselor, from November 2007 through
February 2009, with a standardized questionnaire to identify
demographic features, cigarette smoking history, medication
history, past and present clinical diseases, and surgeries. A
detailed pedigree was obtained, including race/ethnicity and
a history of fetal demise or stillbirth. Social history including
vocation and artistic experience was collected.
Statistics were performed by JMP (SAS Institute, Cary,
NC). A two-tailed Student’s t-test for continuous variables
and Pearson’s Chi-Squared test for categorical variables were
used for comparative statistics when comparators had more
than ﬁve observations. A P-value <.05 was accepted as
signiﬁcant. No correction for multiple comparisons was
made.
The Hardy-Weinberg statistics were applied to the geno-
types detected in the ACT study to calculate the S allele
frequency in that study population. The total number of S
alleles detected in the ACT study (812) was divided by the
total number of alleles (15320) thus determining the S allele
frequency (5.3%). The S allele frequency was squared and
then multiplied by the total number of participants in the
ACT study (7660) to determine the predicted number of
individuals with the PiSS genotype (21).
A comprehensive literature review was conducted by two
investigators (DM, CS). A recent meta-analysis of chronic
obstructive pulmonary disease (COPD) risk associated with
PiS alleles [4] was the starting point for our evaluation since
the119articlesreviewedindetailreportedonlysevenarticles
that mentioned cases of the PiSS genotype. These seven
articles were reviewed for any other clinical information in
addition to COPD. In addition, testing studies that reported
outcomes on more than 100 patients were reviewed from
the dataset of de Serres [5] to ascertain if information was
included on individuals that were PiSS. References of articles
that discuss cases of PiSS were indexed and translations
of articles in other languages from English were obtained.
Tables of general population and disease speciﬁc testing were
constructed.
3. Results
The ACT study and the Alpha-1 Foundation Research
Registry enrollments by genotype as of January 1, 2008 are
shown in Table 1. The ACT study identiﬁed 34 individuals
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Figure 1: Percentage of seasonal/environmental allergies, medi-
cation allergies, or both seasonal/environmental and medication
allergies in the study cohort (N = 19) compared to the controls
(N = 29).
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Figure 2: Lifetime medication use percentage in the study cohort
(N = 19) compared to the controls (N = 29).
with the PiSS genotype. Eight of these individuals chose
to not continue in the longitudinal outcome study after
receiving their results per study protocol [6], and contact
information was not available. Sixteen of the remaining 26
individuals were interviewed. One of the 26 identiﬁed indi-
viduals died prior to being interviewed. The remaining nine
individuals were not interviewed due to incorrect contact
information (N =6) or did not return three telephone calls
(N =3).
Five individuals in the Registry were identiﬁed with
the PiSS genotype. One of these ﬁve individuals was also
in the ACT study. Therefore, four additional individuals
were identiﬁed for the current study. Three individuals
were interviewed. The remaining person did not return the
researcher’s phone calls on three occasions but reported
asthma in the Registry database. Therefore, 19 individuals
comprise the current PiSS study cohort.
3.1. Participants of Current Study. Table 2 shows patient
demographics for the cohort of the PiSS genotype and
the control participants with the PiMM genotype. Eigh-
teen participants were non-Hispanic Caucasian. One ACT
study participant was Hispanic. There was no diﬀerence
in smoking status, smoking duration, secondhand smoking
incidence, or secondhand smoking duration between par-
ticipants with the PiSS genotype and the PiMM genotype.
Table 3 listsphysician-reporteddiagnosesforCOPD,asthma,
and hepatic steatosis (fatty liver) and self-reported jaundice,
frequent pneumonia, and bronchitis. Lung disease symp-
toms, present in 11 of 19 (57.9%) participants from thePulmonary Medicine 3
Table 1: Published research on Alpha-1 antitrypsin population genetics when PiSS was reported.
Author N PiMM PiMS PiSS PiSS lung disease N (%) PiSZ PiMZ PiZZ Other Unknown
General population studies
Dahl et al. [7]∗ 9187 8182 500 12 0% 10 477 6 0 0
Horne et al. [8] 554 484 30 2 NA† 02 10 7 0
Gulsvik and Fagerhol [9] 1258 1102 60 2 100% 3 55 1 35 0
Referred population studies
Brantly et al. [10] 442 194 59 16 NA 23 56 94 0 0
Webb et al. [11] 500 442 30 1 100% 0 18 0 6 3
Fagerhol and Hauge [12] 503 434 27 3 100% 2 14 3 20 0
Lochon et al. [13] 433 366 43 1 0% 1 18 1 3 0
Zorzetto et al. [14] 1399 900 297 8 NA 10 144 1 39 0
Current study
McGee et al. Alpha-1 Coded Testing Study 7660 3954 549 34 8/16‡ (50.0%) 193 2632 238 60 N/A
Alpha-1 Foundation Research Registry 3090 0 26 5 5§ (100%) 144 777 1577 55 506
∗Included in the MM genotype is the E polymorphism which is situated in the 3’ noncoding enhancer binding region.
†NA: Not Available. This study did not indicate whether the individuals with the PiSS genotype were diagnosed with any lung/liver disease or had the presence
of any symptoms.
‡Sixteen of 34 individuals tested were interviewed to obtain this frequency of any lung disease.
§Registry participants identiﬁed the presence of lung disease at study entry. Three of these are included in the study cohort of this paper. Lung diseases
reported in all 5 individuals with PiSS include COPD, N =2, Asthma, N =3, and Frequent pneumonia, N =2.
Table 2: Demographics.
PiMM (N =29) PiSS (N =19) P-value
Age 46.4±17.7 46.9±15.5 .46
Race 28 White, 1 Native
American 18 White .76
Hispanic ethnicity 1 participant 1 participant
Sex 21 Female, 8 Male 15 Female, 4
Male .61
Smoking history 13 9 .95
% Lung disease 37.9% 57.9% .17
% Liver disease 13.8% 26.3% .28
One control participant reported both White and Native American races
which makes 1 participant in each group not white.
cohort of the PiSS genotype, were not statistically higher
than lung disease symptoms in 11 of 29 (37.9%) participants
in the control group (P =.17). In addition, there was no
correlation in univariant or multivariant analyzes between
genotype, cigarette smoking intensity or duration, and the
presence of lung disease. Jaundice was not a reason for ACT
study or Registry enrollment in any individual with PiSS.
Participants were also asked about other diagnosed con-
ditions. Table 4 represents the conditions that were reported
in at least two individuals from either the study or control
populations. Anxiety and/or depression and/or bipolar dis-
order were reported in 47.4% of the participants with PiSS
and51.7%oftheparticipantswithPiMM(P =.77).Avariety
of conditions were reported with unusual disease states
reported in both the study cohort and the matched controls.
For example, ﬁbromyalgia, hemolytic uremic disorder, and
Hirschsprung’s disease were reported in single instances in
thecontrolpopulation.Downsyndrome,endometriosis,and
Sj¨ ogren’s syndrome were also reported in single instances in
the study population.
To address the possibility that the PiSS genotype in a
fetusisassociatedwithdecreasedviability,adetailedpedigree
was obtained from each participant in the cohort of the PiSS
genotype. This included information regarding miscarriages
and stillbirths. The number of miscarriages and the number
of stillbirths reported in each participant’s biological parents
were compared to the general population incidences for
miscarriages and stillbirths. A detailed pedigree was not
obtained on one participant who was removed from this
analysis.
A total number of 34 conceptions and 29 live births
were reported in the 18 participants in this cohort. A total
number of 79 conceptions and 68 live births were reported
in the biological mother of the participants with the PiSS
genotype. Thus, the incidences of fetal loss are 14.7% and
13.9%, respectively.
Participants were questioned regarding a history of
allergies. Figure 1 illustrates the percentage of participants
in both the study and control populations that reported
seasonal/environmental allergies, medication allergies, or
a history of both seasonal/environmental and medication
allergies. There were no diﬀerences in the reported allergy
distribution although individuals with the PiSS genotype
trended toward having more medication allergies (P =.11).
Figure 2 illustrates the percentage of participants in
both the study and control populations that reported a
lifetime history of using bronchodilators, corticosteroids,
and psychiatric medications. There was no diﬀerence in use
for bronchodilators (P =.44), corticosteroids (P =.96), or
psychiatric medications (P =.95) from the control popula-
tion.4 Pulmonary Medicine
Table 3: Lung and liver disease in 19 individuals with the PiSS genotype and 29 controls with the PiMM genotype.
PiMM (N =29) PiSS (N =19)
Diagnosis N (%)∗ Age of diagnosis† Age at interview† N (%)∗ Age of diagnosis† Age at interview†
COPD‡ 5 (17.24%) 46±13.47 53±13.78 3 (15.79%) 34.33±6.03 62±5.20
Asthma 4 (13.79%) 21.25±14.5 41.25±6.80 5 (26.32%) 24.2±16.71 51.6±14.91
Frequent Pneumonia 2 (6.90%) 8.5±2.12 39.5±10.60 3 (15.79%) 11.67±9.71 48±14.73
Frequent Bronchitis 1 (3.45%) 40 53 2 (10.53%) 15±7.07 45±8.49
Other lung disease 3 (10.34%) NA 49.67±30.17 4 (21.05%) NA 50.5±12.18
Jaundice 3 (10.34%) 0 29.33±16.17 4§ (21.05%) 13.5±15.93 64.5±6.56
Hepatic Steatosis 1 (3.45%) 35 64 1 (5.26%) 34 35
None 17 (58.62%) N/A 47.06±17.61 7 (36.84%) N/A 38±16.39
∗Participants may have >1 diagnosis.
†Mean ±standard deviation.
‡COPD diagnosis was physician diagnosed with either emphysema or chronic bronchitis.
§One participant had jaundice as a newborn and later diagnosed with Sj¨ ogren’s syndrome at 48 years of age and had elevated liver enzymes that resolved after
a year of prednisone treatment.
N/A: not applicable, NA: Not available.
Table 4: Diagnoses with >2 individuals reporting disease.
Diagnosis∗ MM
N = 29
SS
N = 19
Anxiety and/or depression
and/or bipolar 15 9
Hypertension 7 5
Heart disease 3 3
Diabetes 2 3
Hypothyroidism 5 2
Irritable Bowel Syndrome 1 2
Osteoporosis 0 3
Arthritis 4 2
Hypercholesterolemia 2 2
Sleep problems 3 0
Acid Reﬂux/GERD 2 1
Migraines 2 0
∗Diagnoses listed are ones reported by two or more participants.
The social history of each participant was also obtained,
speciﬁcally the presence of a vocation that involved an
artistic experience. The examples of artistic experiences
listed in the scripted question included music, art, dance,
theater,reading,orwriting.Eleven(57.9%)participantswith
the PiSS genotype reported having an artistic experience
compared with 17 (58.6%) participants with the PiMM
genotype (P =.96).
3.2. Literature Review. A comprehensive meta-analysis of
COPD risk associated with PiS alleles performed by Dahl et
al. [4] reviewed seven studies with subjects identiﬁed as PiSS.
Many research studies addressing the population genetics of
Alpha-1 did not speciﬁcally list the number of individuals
with the PiSS genotype found due to the small number of
individuals detected. Table 1 lists research articles that did
report the number of individuals with the PiSS genotype.
Table 5: Case-control series of individuals with COPD and asthma
in which at least one individual with the PiSS genotype has been
identiﬁed.
Case Control
COPD
Kueppers et al. [15] 0/114 (0%) 1/114
(0.9%)
Lieberman et al.
[16] 3/965 (0.31%) 1/1380
(0.07%)
Sandford et al. [17] 2/193 (1.04%) 0/73 (0%)
Mittman et al. [18] 1/240 (0.42%) 0.1/240
(0.04%)
Allergy and nonatopic infantile asthma
Ihrig et al. [19] 0/138 (0%) 5∗/700
(0.71%)
Arnaud et al. [20] 2/298 (0.67%) 23/1653
(1.39%)
∗Not indicated whether these ﬁve participants were PiSS or PiSZ genotypes.
The literature was also examined for studies that
addressed the question of whether there is excess disease in
a population of individuals with the PiSS genotype. Table 5
lists four case-control studies examining the presence of
COPD. Also listed in Table 5 are two case-control studies
that reported the presence of allergy and nonatopic infantile
asthma.
4. Conclusions
Few previous studies have characterized the clinical char-
acteristics of individuals with the PiSS genotype, an AAT
polymorphism that is associated with mean serum levels of
AAT approximately 60% of predicted, similar to individuals
with the PiMZ genotype. Deﬁning the risk of COPD
associated with the PiMZ genotype has been controversial
[7, 17] despite having many more subjects (2%-3% of thePulmonary Medicine 5
population) to evaluate. The goal of this study was to deﬁne
if there might be an independent risk for lung disease
associated with the PiSS genotype and to evaluate whether
additional clinical conditions not associated with lung or
liver disease are increased in prevalence in individuals with
the PiSS genotype.
Individuals with the PiSS genotype are uncommonly
encountered in clinical practice. However, the S allele fre-
quency in ACT was 5.3%. When applying Hardy-Weinberg
statistics to the S allele frequency of participants in the
ACT study, we would predict 21 individuals with PiSS and
found 34 individuals with PiSS. This suggests that there
could be either an excess of symptoms that foster ACT study
participation or family testing from families with S alleles.
The PiSS genotype does not appear to be associated with
excess fetal demise. The reported incidence of miscarriage
and stillbirth in our cohort of individuals with the PiSS
genotype is similar to the reported general population risk
of miscarriage of 10%–15% [21]. Ourpopulation is not large
enoughandtoobiasedtodeﬁnewhetherasurvivaladvantage
exists for the PiSS genotype.
Our study noted a higher than expected prevalence of
lung disease in the individuals with the PiSS genotype;
however, the same was noted in the control population.
Eight of 16 individuals testing in the ACT study with PiSS
had physician-diagnosed lung disease, with four of these
asthma or COPD. Given the prevalence of both asthma and
COPD, these cross-sectional data appear high. However, the
incidence of asthma or COPD in the population of PiMM of
the ACT study is 7/29 (24.1%). Assuming the null hypothesis
that individuals with obstructive lung diseases are likely to
test for AAT deﬁciency equally among genotypes, the slight
excess in individuals with PiSS with COPD and asthma
raises more questions than it answers. Unfortunately, the
small sample sizes intrinsic to the PiSS polymorphism will
make future studies of this association diﬃcult to adequately
enroll.
This study also found a high prevalence of smoking in
both the study and control groups with obstructive lung
disease. We did our best to adequately evaluate smoking
histories. As listed in Table 2, there was no statistical diﬀer-
ence in the number of smokers in the PiSS cohort and the
controls. Cigarette smoking is a retrospective data point and
there could be diﬀerences in other environmental exposures
that were not ascertained. Furthermore, cigarette smoking
may not be a linear covariate in COPD. However, the small
number of participants prevents a more comprehensive
analysis of the interaction between genetics, environment,
and the presence of lung symptoms.
There is incomplete characterization of whether liver
disease is increased in individuals with the PiS allele. Liver
disease has been reported in individuals with both the
PiMS and PiSZ genotypes, although the frequency is less
than in individuals with the PiZZ genotype [22]. Because
cryptogenic cirrhosis is frequent in hepatology clinics, the
association of these genotypes with clinical liver disease
remains undermined. Our series would suggest that the
incidence of jaundice (4 of 19 ACT study or Registry par-
ticipants) is higher than predicted in a general population,
although no cases of cirrhosis were identiﬁed. Although
jaundice was not the reason for study enrollment in any
individual, family members with AAT deﬁciency may have
prompted testing and could have other genetic risks for liver
disease.
Other associations of AAT alleles and clinical conditions
have been rarely reported. Schemel recently suggested that
the PiS allele was associated with a personality phenotype
characterized by “intense creative energy” (ICE) [23]. ICE
was created to describe an artistic personality, often associ-
ated with a mood disorder. A majority of individuals with
at least one S or Z mutation in his cohort were artists
of some persuasion. In fact, all three of the individuals
in his cohort that were PiSS had an ICE phenotype [23].
For this reason, we asked the questions associated with
this observation in an independent population ﬁnding. In
our current study, 6/19 (31.6%) of individuals in the study
cohort reported both a history of anxiety and/or depression
and/or bipolar disorder and artistic experience. In our
control population, the combination of artistic expression
and mood disorder was 8/29 (27.6%). Furthermore, equal
numbers of individuals in the study and control populations
were receiving medications to treat psychiatric conditions.
Thus we would suggest that there are not mood distur-
bances or an excess of psychiatric diseases in the PiSS
genotype.
There are many limitations to our study. Spirometry data
were not available; therefore, the severity of lung disease
was unable to be assessed. One possible reason for the high
incidence of lung and/or liver symptoms could be due to
sampling bias. The participants from the ACT study are
more likely to be individuals with a family history of AAT
deﬁciency or current clinical symptoms prompting AAT
testing. The data for this study are derived from participant
interviews and may be subject to miscommunication from
their physicians. The individuals in the study and control
groups diﬀered in the years from diagnosis to time of
interview. This discrepancy is a result of the fact that
individuals chose when to participate in the ACT study and
be tested for AAT deﬁciency. We also recognize that the
number of individuals available for interview in this study
is too low to fully characterize the PiSS genotype, since
other clinical conditions might occur with low prevalence
and reported conditions may not appear as signiﬁcant
in a larger sample size. Taking into account this small
sample size further, we cannot make generalizations about
the clinical signiﬁcance of the PiSS genotype. However,
this case study does provide an insightful perspective
into the relatively unknown clinical picture of the PiSS
genotype.
The incidence of lung disease in the individuals with
the PiSS and PiMM genotypes was higher than expected,
however, not signiﬁcantly signiﬁcant. Therefore, larger epi-
demiological studies would be needed to determine if the
PiSS genotype is associated with an increased risk for lung
disease. In conclusion, we were not able to illustrate a
diﬀerence in obstructive lung disease incidence between the
PiSS genotype and the PiMM genotype in this largest case
series reported to date.6 Pulmonary Medicine
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